Welcome to our dedicated page for Marinus Pharmace news (Ticker: MRNS), a resource for investors and traders seeking the latest updates and insights on Marinus Pharmace stock.
Marinus Pharmaceuticals (MRNS) is a clinical-stage biopharma company advancing ganaxolone for rare neurological disorders, including epilepsy and CDKL5 deficiency disorder. This page aggregates official announcements and verified updates about the company's therapeutic developments and regulatory progress.
Investors and researchers will find timely updates on clinical trial outcomes, FDA designations, and strategic partnerships. Our curated collection ensures access to primary source materials including press releases, regulatory filings, and milestone achievements.
Key content includes updates on ganaxolone's development pathway, orphan drug status details, and analyses of the company's position in neurotherapeutics. All materials are sourced directly from company communications to ensure accuracy.
Bookmark this page for streamlined tracking of MRNS's progress in addressing high-need neurological conditions through innovative therapeutic development.
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) announced the grant of inducement awards to three new employees, comprising non-qualified stock options for 18,263 shares of common stock. The options have an exercise price of $7.79 per share, equivalent to the closing stock price on March 11, 2022. These options will vest incrementally over four years, with 25% vesting after one year and the remainder vesting monthly thereafter. This grant aligns with Nasdaq Listing Rule 5635(c)(4), aimed at incentivizing new hires within the company.
Marinus Pharmaceuticals (Nasdaq: MRNS) has announced a delay in its RAISE Phase 3 trial for IV ganaxolone due to the COVID-19 Omicron variant's impact on hospital resources and clinical supply interruptions. The trial completion is now expected in the second half of 2023. Additionally, the company aims to resolve supply issues and enhance manufacturing processes to achieve a longer product shelf life. The initiation of two related trials has also been pushed back by six months, but interest in the RAISE trial remains robust with 48 sites activated.
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) announced a scheduled business update and preliminary financial results for Q4 and fiscal year 2021 on March 21, 2022. The conference call will take place at 8:00 a.m. ET, where the company will discuss its innovative therapeutics aimed at treating seizure disorders, including their lead drug, Ganaxolone. Ganaxolone is designed to enhance GABAA receptor activity, offering potential benefits for both adult and pediatric patients.
Marinus Pharmaceuticals (MRNS) announced the grant of inducement awards to six new employees, including non-qualified stock options for 75,938 shares and restricted stock units for 8,600 shares. The stock options have an exercise price of $11.93 per share, equal to the closing price on February 9, 2022. These awards are designed to attract talent as per Nasdaq Listing Rule 5635(c)(4). The stock options will vest 25% after one year, with the remainder vesting in monthly installments over three years. The restricted stock units fully vest after one year.
Marinus Pharmaceuticals (NASDAQ: MRNS) announced positive preliminary results from an in vivo study of its M2 metabolite, showing no genotoxicity. The study assessed bone marrow micronuclei formation and liver comet morphology. Additionally, the company’s marketing authorization application for ganaxolone in CDKL5 deficiency disorder will shift to a standard review timeline, with an extended Day 120 clock stop by three months. The EMA's opinion on the application is anticipated by year-end 2022. The M2 metabolite study's final report is expected by the end of February 2022.
Marinus Pharmaceuticals (MRNS) has announced the grant of inducement awards to five new employees, including non-qualified stock options for 42,810 shares and restricted stock units for 10,800 shares. The stock options have an exercise price of $11.11 per share, aligning with the closing price on January 11, 2022. Vesting for stock options will occur over four years, while restricted stock units will vest fully after one year. These grants comply with Nasdaq Listing Rule 5635(c)(4), intended to incentivize employee recruitment.
Marinus Pharmaceuticals (Nasdaq: MRNS) announced its participation in two key investment conferences. Management will present at the H.C. Wainwright Bioconnect Conference on January 10, at 7:00 a.m. ET, featuring CEO Scott Braunstein and CFO Steven Pfanstiel. The 40th Annual J.P. Morgan Healthcare Conference is scheduled for January 13, at 8:15 a.m. ET, also with Scott Braunstein presenting. Both events will be available via webcast, allowing stakeholders to engage with the company's mission in treating seizure disorders.
Marinus Pharmaceuticals announced the grant of inducement awards to five new employees, which includes non-qualified stock options for 59,750 shares and restricted stock units for 3,400 shares. The stock options have an exercise price of
Marinus Pharmaceuticals (NASDAQ: MRNS) announced new clinical trial data to be presented at the American Epilepsy Society Annual Meeting in Chicago. The data includes findings on ganaxolone's safety and efficacy in treating CDKL5 deficiency disorder and super-refractory status epilepticus. Key results show a 30.1% to 53.8% reduction in seizure frequency among patients over 12 months. The company will hold a virtual investor event on December 6 to discuss these findings.
Marinus Pharmaceuticals (MRNS) announced the acceptance of nine abstracts for presentation at the American Epilepsy Society's Annual Meeting in Chicago from December 3 to 7, 2021. Key highlights include clinical data on ganaxolone in CDKL5 deficiency disorder, which is currently under FDA review, as well as findings for tuberous sclerosis complex and Lennox-Gastaut syndrome. CEO Scott Braunstein emphasized the significance of new safety and efficacy data for ganaxolone. Additionally, a virtual investor event is scheduled to provide updates on their pipeline programs.
FAQ
What is the current stock price of Marinus Pharmace (MRNS)?
What is the market cap of Marinus Pharmace (MRNS)?
